AXSM · Axsome Therapeutics, Inc.

Track AXSM — free

$218.20 +2.51 (+1.16%) At close · Aug 19

Market Cap

$11.30B

52.38M

Up next

Next earnings call

Nov 13, 2026 Est · unconfirmed · in 12 wks

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed Aug 10, 2026

AI Brief

TL;DR.

Bullish

Bearish

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Ask ALVIS about this →

Equibles Rating

blended score · not investment advice

Overall

Buy

SellHoldBuy

Technical Neutral Momentum Strong Sentiment Neutral Fundamentals Strong Quant / Vol Moderate

Market backdrop VIX 14.9 · calm Equity put/call 0.52

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg +14%

above

Price vs 50-day avg −7%

below

RSI (14) 45

neutral

MACD trend Positive

52-week position 74%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Strong

1-month return −9%

trailing

6-month return +34%

trailing

YTD return +19%

this year

Relative strength +22%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $234 › 200d $191 — 50d above 200d

Institutional flow Accumulating

+22% holders QoQ · +138 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

6.51% of float · ▲ +12.7% MoM · 5.1 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

506 holders — near 3-yr high, broad support

Squeeze score 64

elevated · 0–100

Fundamentals

Strong

EPS growth +39%

Y/Y

Free cash flow $-93.9M

Balance sheet $135.2M

net cash

Quant / Vol

risk profile

Moderate

Volatility 43%

annualized · 1-yr

Max drawdown −19%

past year

ATR 3.8%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral

1 · 4 · 2

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+14% Bullish

Price vs 50-day avg

−7% Bearish

RSI (14)

45 Neutral

MACD trend

Positive Bullish

52-week position

74% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 2 of 6

Trend (MA cross) No cross

50d $234 › 200d $191 — 50d above 200d

Institutional flow Accumulating

+22% holders QoQ · +138 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

6.51% of float · ▲ +12.7% MoM · 5.1 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

506 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $111 Now $218 · 74% Range high $255

vs 200-day avg +14% vs 50-day avg -7%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
AUVELITY net product revenue	$180.3M	2Q 2026	—
AUVELITY payer coverage across all channels	89%	second quarter of 2026	—

AUVELITY payer coverage in commercial channel	82%	second quarter of 2026	—

AUVELITY payer coverage in government channel	100%	second quarter of 2026	—

AUVELITY prescriptions written	266,000	second quarter of 2026	—

AUVELITY sales force	630	2Q 2026	—

Commercial covered lives (SYMBRAVO)	56%	2Q 2026	—
Medicare and Medicaid covered lives (SYMBRAVO)	57%	2Q 2026	—
NBRx growth QoQ	26%	2Q 2026	—
Patients treated since launch	350,000	2Q 2026	—
Patients treated since launch (SUNOSI)	109,000	2Q 2026	—
Patients treated since launch (SYMBRAVO)	19,500	2Q 2026	—
QoQ growth in activated new writers	21%	2Q 2026	—
SUNOSI payer coverage across all channels	82%	second quarter of 2026	—

SUNOSI payer coverage in commercial channel	96%	second quarter of 2026	—

SUNOSI payer coverage in government channel	59%	second quarter of 2026	—

SUNOSI prescriptions written in the U.S.	61,000	second quarter of 2026	—

SUNOSI royalty revenue	$2.02M	FY2026 Q2	+86.5%

SUNOSI TRx	61,000	2Q 2026	—
SYMBRAVO payer coverage across all channels	57%	second quarter of 2026	—
SYMBRAVO prescriptions written	23,500	second quarter of 2026	—

Total covered lives	89%	2Q 2026	—
Total covered lives (SUNOSI)	82%	2Q 2026	—
Total Net Product Revenue	$218.4M	2Q 2026	—
TRx in 2Q 2026 (SYMBRAVO)	23,500	2Q 2026	—
Unique writers since launch	69,000	2Q 2026	—
Unique writers since launch (SUNOSI)	17,000	2Q 2026	—
Unique writers since launch (SYMBRAVO)	4,700	2Q 2026	—
AUVELITY net product sales	$507.1M	full year 2025	—
SUNOSI net product revenue	$124.8M	full year 2025	—
SUNOSI net product sales	$120.1M	full year 2025	—
SYMBRAVO net product sales	$6.6M	full year 2025	—
SYMBRAVO payer coverage	52%	fourth quarter 2025	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
AXSM Axsome Therapeutics, Inc. this stock	$11.30B	+19.5%	+65.5%	—	6.5%
ONC BeOne Medicines Ltd.	$535.83B	+24.0%	+22179.2%	823.9	0.1%
VRTX Vertex Pharmaceuticals Inc / Ma	$133.88B	+21.8%	+46.2%	30.8	1.6%
REGN Regeneron Pharmaceuticals, Inc.	$84.27B	+8.9%	+20.8%	20.3	3.3%
ARGX Argenx SE	$61.75B	+22.8%	—	—	2.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

506

% held: 76.3%
Net QoQ: +703.9K sh
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

375

View

Short & Settlement

Short Interest Rising

Shares short

3.4M

Days to cover: 5.1d
Change: +383.4K sh

View

Short Volume

Short vol %

61%

As of: Aug 19, 2026

Short Total

View

Fails to Deliver

FTD shares

Value: $4.4K
As of: Jul 29, 2026

View

Off-Exchange

Off-exchange %

44.4%

Week of: Jul 13, 2026

Off-exch Lit

View

Smart Money

Congressional Trades Buy

Member

Christopher L. Jacobs

Amount: $15.0K–$50.0K
Traded: Jun 16, 2022

View

Financials

Revenue (FY)

$638.5M

Net income (FY): $-183.2M
EPS diluted: $-3.68

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 10, 2026
This year: 18

View

Proposed Sales

Value

$71.2K

Shares: 286
Filed: Jun 11, 2026

View

Earnings & Events

Earnings Calls

Last call

Aug 10, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
AXSM	+1.7%	-8.9%	+33.7%	+0.1%	+19.5%
SPY	-0.4%	+2.9%	+11.6%	+3.0%	+12.8%
vs SPY	+2.1%	-11.8%	+22.1%	-2.9%	+6.7%

Key facts CIK 1579428 CUSIP 05464T104 13F (30d) 470 filings 464 filers Visit website Investor relations

AXSM · Axsome Therapeutics, Inc.

Price & Indicators

Up next

AI Brief

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance